scholarly journals Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma

2014 ◽  
pp. 43
Author(s):  
Richard Grose ◽  
Stacey Coleman ◽  
Hemant Kocher
Keyword(s):  
Hepatocellular Carcinoma ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth ◽  
Potential Target ◽  
Fibroblast Growth Factor Family

Characterization of int-2: a member of the fibroblast growth factor family

1990 ◽  
Vol 1990 (Supplement 13) ◽  
pp. 87-96 ◽  
Author(s):  
C. DICKSON ◽  
P. ACLAND ◽  
R. SMITH ◽  
M. DIXON ◽  
R. DEED ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor Family

scholarly journals Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma

Hepatology ◽  
2008 ◽  
Vol 47 (4) ◽  
pp. 1211-1222 ◽  
Author(s):  
Jin-Ping Lai ◽  
Dalbir S. Sandhu ◽  
Chunrong Yu ◽  
Tao Han ◽  
Catherine D. Moser ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Growth Factor Signaling ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor Signaling

Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis

Hepatology ◽  
2011 ◽  
Vol 53 (3) ◽  
pp. 854-864 ◽  
Author(s):  
Christine Gauglhofer ◽  
Sandra Sagmeister ◽  
Waltraud Schrottmaier ◽  
Carina Fischer ◽  
Chantal Rodgarkia-Dara ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Growth Factor ◽  
Cell Survival ◽  
Fibroblast Growth Factor ◽  
Human Hepatocellular Carcinoma ◽  
Fibroblast Growth ◽  
Fibroblast Growth Factor 8

scholarly journals Decoding the Genetic Alterations in Genes of Fibroblast Growth Factor Family and Their Possible Association with HNSCC

2021 ◽  
pp. 698-710
Author(s):  
A. Akshaya ◽  
J. Vijayashree Priyadharsini ◽  
A. S. Smiline Girija ◽  
P. Sankar Ganesh ◽  
Nidhi Poddar
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Demographic Data ◽  
Primary Tumour ◽  
Genetic Alterations ◽  
Fibroblast Growth ◽  
Heparin Binding ◽  
Fibroblast Growth Factor Family ◽  
Significant Difference ◽  
Cancer Phenotypes

Introduction: HNSCC is a type of cancer in the oral and pharynx region. Several mutations/variations are observed in these cancer phenotypes. Fibroblast growth factor belongs to the family of heparin binding growth factors. FGFs are multifunctional proteins with a wide variety of effects; they are most commonly mitogens. Their expression pattern correlates with invasion of HNSCC. Aim: To assess the genetic alterations in genes of the fibroblast growth factor family and their association with HNSCC. Materials and Methods: The demographic data and samples of 528 HNSCC patients was collected from the cBioportal database. Oncoprint analysis was done to assess the amplification and genetic alterations of the members of the FGF gene family. String analysis was performed to evaluate the protein-protein interaction. The information about previous reported mutation and correlation with novel and reported mutation was obtained using GnomAD analysis. Results and Discussion: FGF3,4 and 19 genes showed maximum variation (25%). FGF4 and FGF19 genes showed maximum amplification in addition to deletion mutation. Excitingly FGF3, FGF4 and FGF19 genes showed similar amplification patterns in most of the HNSCC patients. Statistical significant difference in the gene expression of FGF3 9.578 x 10-3 observed between normal and primary tumour. S.  Findings showed many novel mutations and also 4 reported mutations ie:FGF1, FGF12, FGF20, FGF21 Conclusion: Our present study concludes that more evidence is required to confirm their association with HNSCC.

scholarly journals FGF19–FGFR4 Signaling in Hepatocellular Carcinoma

Cells ◽  
2019 ◽  
Vol 8 (6) ◽  
pp. 536 ◽  
Author(s):  
Aroosha Raja ◽  
Inkeun Park ◽  
Farhan Haq ◽  
Sung-Min Ahn
Keyword(s):  
Hepatocellular Carcinoma ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Growth Factor Receptor ◽  
Fibroblast Growth ◽  
Binding Modes ◽  
Aberrant Expression ◽  
Promising Target ◽  
Recent Developments ◽  
Driver Pathway

Hepatocellular carcinoma (HCC) is the sixth most common type of cancer, with an increasing mortality rate. Aberrant expression of fibroblast growth factor 19–fibroblast growth factor receptor 4 (FGF19–FGFR4) is reported to be an oncogenic-driver pathway for HCC patients. Thus, the FGF19–FGFR4 signaling pathway is a promising target for the treatment of HCC. Several pan-FGFR (1–4) and FGFR4-specific inhibitors are in different phases of clinical trials. In this review, we summarize the information, recent developments, binding modes, selectivity, and clinical trial phases of different available FGFR4/pan-FGF inhibitors. We also discuss future perspectives and highlight the points that should be addressed to improve the efficacy of these inhibitors.

Sign in / Sign up

Export Citation Format

Share Document